Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment
H Swaminathan, K Saravanamurali, SA Yadav - Medical Oncology, 2023 - Springer
As the most frequent and vulnerable malignancy among women, breast cancer universally
manifests a formidable healthcare challenge. From a biological and molecular perspective, it …
manifests a formidable healthcare challenge. From a biological and molecular perspective, it …
[HTML][HTML] Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene …
Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
The treatment of metastatic castration-resistant prostate cancer (mCRPC) has been
fundamentally transformed by our greater understanding of its complex biological …
fundamentally transformed by our greater understanding of its complex biological …
[HTML][HTML] Poly (ADP-ribose) polymerase inhibitors have comparable efficacy with platinum chemotherapy in patients with BRCA-positive metastatic castration-resistant …
Context Testing for mutations in Breast Cancer Gene 1/2 (BRCA) has emerged as a novel
decision-making tool for clinicians. Patients with metastatic castration-resistant prostate …
decision-making tool for clinicians. Patients with metastatic castration-resistant prostate …
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis …
Background Evidence suggests proton pump inhibitor (PPI) use may attenuate the effect of
abiraterone acetate plus prednisone (AAP) in metastatic prostate cancer via the modification …
abiraterone acetate plus prednisone (AAP) in metastatic prostate cancer via the modification …
Therapeutic potential of vasculogenic mimicry in urological tumors
X Lin, S Long, C Yan, X Zou, G Zhang, J Zou… - Frontiers in …, 2023 - frontiersin.org
Angiogenesis is an essential process in the growth and metastasis of cancer cells, which
can be hampered by an anti-angiogenesis mechanism, thereby delaying the progression of …
can be hampered by an anti-angiogenesis mechanism, thereby delaying the progression of …
Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of …
Z Luo, B Zhu, H Xu, L Chen, X Song, Y Wang… - Frontiers in …, 2023 - frontiersin.org
Background Olaparib has been proven for the treatment of metastatic castration-resistant
prostate cancer (mCRPC). This meta-analysis aims to comprehensively evaluate the efficacy …
prostate cancer (mCRPC). This meta-analysis aims to comprehensively evaluate the efficacy …
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a …
E Castro, D Wang, S Walsh, S Craigie… - Prostate Cancer and …, 2024 - nature.com
Background Without head-to-head trials between talazoparib+ enzalutamide (TALA+ ENZA),
olaparib+ abiraterone acetate (OLAP+ AAP), and niraparib plus AAP (NIRA+ AAP) the ability …
olaparib+ abiraterone acetate (OLAP+ AAP), and niraparib plus AAP (NIRA+ AAP) the ability …
[PDF][PDF] Identifikation neuer diagnostischer Biomarker für das Prostatakarzinom
C Schreiner - repositorium.meduniwien.ac.at
Hintergrund: Das Prostatakarzinom ist die häufigste Krebserkrankung unter Männern in
Österreich. Im Jahr 2019 lag der prozentuale Anteil an der Gesamtheit der …
Österreich. Im Jahr 2019 lag der prozentuale Anteil an der Gesamtheit der …
[HTML][HTML] PARP Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A …
Advancements in molecular diagnostics and targeted therapies of the past years brought the
era of precision medicine in prostate cancer care. The evolving accessibility and global …
era of precision medicine in prostate cancer care. The evolving accessibility and global …